Abstract Number: 1945 • ACR Convergence 2021
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies
Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…Abstract Number: 1943 • ACR Convergence 2021
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…Abstract Number: PP02 • ACR Convergence 2021
Leveraging Digital Health Tracking to Improve Arthritis Management
Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…Abstract Number: PP04 • ACR Convergence 2021
Dual Roles: Thriving with SLE as a Medical Student
Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…Abstract Number: PP12 • ACR Convergence 2021
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…Abstract Number: 1939 • ACR Convergence 2021
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…Abstract Number: 1918 • ACR Convergence 2021
Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
Background/Purpose: Long-term outcomes following a diagnosis of rheumatoid arthritis associated interstitial lung disease (RA-ILD) are poor, with a median survival estimated between 3 to 8…Abstract Number: 1821 • ACR Convergence 2021
Role of Patient Organizations in Implementation of Recommended Non-pharmacological Treatment Modalities in Spondyloarthritis: Evidence for the Effectiveness of Self-management Strategies
Background/Purpose: This study aimed to characterize the impact of pt advocacy group membership and its association with NPTM frequency and clinical parameters in axSpA pts.…
- « Previous Page
- 1
- …
- 646
- 647
- 648
- 649
- 650
- …
- 2425
- Next Page »